Prevalence of Sexual Dysfunction in Mexican Women with Rheumatoid Arthritis

Wendoline Rojo-Contreras, Valeria Díaz-Rizo, Xochitl Trujillo, Miguel Huerta, Alberto D. Rocha-Muñoz, Benjamin Trujillo-Hernandez, Alicia Rivera-Cameras, Ingrid P. Dávalos-Rodríguez, and Mario Salazar-Páramo

Abstract: We estimate the prevalence and identified the associated factors of sexual dysfunction in Mexican women with rheumatoid arthritis (RA). A cross-sectional survey was applied to 100 women with RA and compared with 100 healthy, sexually active, adult women. Assessments included an interview using the Female Sexual Function Index (FSFI). Assessment of factors related to sexual dysfunction included gynecologic characteristics, disease activity (DAS-28), and functioning questionnaire (HAQ-DI). Mann-Whitney U test and the Chi-square test were used to compare medians and proportions between the groups. A multivariate logistic regression was performed using sexual dysfunction according to impairments shown by the FSFI. A higher proportion of RA patients had sexual dysfunction compared with controls. Domains with higher impairment in RA patients were desire, arousal, lubrication, and orgasm. A decrease in sexual function correlated with age (r = −0.365 p < 0.001) and higher scores in HAQ-DI (r = −0.261 p = 0.009). Those patients with a higher disability had higher impairments in desire, arousal, lubrication, and satisfaction. In the multivariate analysis, menopause was associated with sexual dysfunction (OR: 10.02; 95% CI: 1.05–95.40, p = 0.04), whereas use of methotrexate was a protective factor (OR: 0.32; 95% CI: 0.11–0.92, p = 0.03). Sexual dysfunction is highly prevalent in Mexican women with RA. Clinicians should systematically evaluate the impairment in sexual function in women with RA.

Keywords: female sexual dysfunction; rheumatoid arthritis; quality of life

1. Introduction

Rheumatoid arthritis (RA) is a chronic inflammatory rheumatic disease characterized by inflammation and progressive joint damage, its prevalence is between 1–2% in the world population [1,2]. In Mexico, the prevalence of RA varies from 0.7% to 2.8%, according to the different regions [3]. Predominantly affecting women aged between 30 and 50 years, around the world RA can affect many quality-of-life components, including a patient’s sexuality [4–6]. Female sexual function (FSF) represents a complex interaction of several components, including anatomic, physiologic, medical, and social aspects that are closely related. Disturbances in one or more of these components result in sexual dysfunction [7]. Different studies have established that approximately 46% to 75% of females with RA had sexual dysfunction (FSD) [4–8]. Sexual function could be affected in RA due to pain, stiffness, disability,
depression, fatigue, as well as the therapy used [9,10]. In Mexico, FSD in healthy women has been reported at 62.1% [11]. Moreover, a study on Mexican RA patients addresses that sexual reproductive health is important in their general health [12].

The Female Sexual Function Index (FSFI) is a self-reported questionnaire constructed to assess six dimensions of sexual function in women with an active sexual life. This index includes the following dimensions: sexual desire, arousal, lubrication, orgasm, and painful intercourse [13]. The FSFI has been validated and can be used to identify an impairment in sexual functioning that may require treatment [14]. A significant decrement in the FSFI scores in patients with RA, compared with controls, was documented. A multiplicity of variables associated with the disease may interact to produce sexual dysfunction, including disease activity, impaired functional performance, extra-articular involvement, and some medications [15,16]. Sexuality is very important in human life, but relevant studies are small among RA patients and differ between populations around the world. Therefore, it is relevant to investigate those variables that influence sexual function. The aim of this work is to identify the prevalence and factors associated with sexual dysfunction in women with RA using a multivariate approach.

2. Materials and Methods

Design: Cross-sectional study. Patients were invited to participate from a rheumatology department in a secondary-care hospital, at the Mexican Institute for Social Security (IMSS) (Guadalajara, Mexico) after being approved by the Hospital’s Ethics Committee.

Subjects: One-hundred adult women with RA, diagnosed according to the 1987 American College of Rheumatology criteria [17], were compared with one-hundred healthy women matched by their range of age, who were enrolled by the department of preventive medicine at the same hospital. The women were included if they were between 18 and 50 years old, self-defined as heterosexual, and were sexually active. Patients with RA and controls were excluded if they were pregnant, had a diagnosis of cervical cancer, or were unable (e.g., lacked the education level) to complete the questionnaires.

2.1. Characteristics of the Interview

A structured questionnaire was applied to the women, all interviewed by two trained researchers (WRC, VDR) who evaluated the socio-demographic and gynecological characteristics, aspects of sexual behavior, and marital status assessment of sexual function through the FSFI [13]. Briefly, this is a questionnaire that includes nineteen items to explore six domains of sexual function such as sexual desire, arousal, lubrication, satisfaction, orgasm, and pain during intercourse. Each question has 5 or 6 choices, assigning 0 to 5; each domain score is multiplied by a factor that transforms the maximum possible total to 6 (for desire the factor is 0.6; for arousal and lubrication, 0.3; for orgasm, satisfaction, and pain, 0.4). The end result corresponds to the sum of domains, ranging the full-scale scoring from 2.0 to 36.0. Lower scores indicate higher sexual dysfunction [13,18,19]. In order to establish a cut-off point to determine whether a patient has impaired sexual function, Wiegel, et al. computed a cut-off point of 26.55 for the full-scale score to identify patients that had sexual dysfunction [20]. Different breakpoints in various populations have been used for the appropriate cut-off point, established in each from a different population sample based on the scores that were less than the 25th percentile; these were obtained in the healthy Mexican women who constituted our comparison group. Based on this approach, the clinical cut-off points for sexual dysfunction were <21.5 for the full-scale score, and as follows for each domain score: desire <2.4, arousal <3.0, lubrication <3.9, orgasm <3.6, satisfaction <3.6, and pain during intercourse <3.6.

2.2. Clinical Assessment in Patients with RA

On the same day, a rheumatologist (ARM, MSP) evaluated the diverse clinical characteristics of the disease in all RA patients, including disease duration, functioning (Health Assessment Questionnaire Disability Index; HAQ-DI) [21], disease activity assessment
(DAS28 score) [22], radiological score in the hands by the Steinbrocker stage [23], and extra-
articular involvement. In addition, we recorded prednisone, methotrexate, and azathioprine use, the serum rheumatoid factor (RF) levels, and erythrocyte sedimentation rate (Westergren method).

2.3. Statistical Analysis

Quantitative variables were expressed as the median and interquartile range (IQR), qualitative variables as frequencies and percentages. Comparisons of the medians between groups were made using the Mann–Whitney U test. The Chi-square test was used to compare the proportions between the two groups. A subgroup analysis was performed to compare the median between quantitative variables in RA patients with sexual dysfunction versus patients without sexual dysfunction. We made Spearman’s correlations between the domains and the general characteristics of the women with RA. A multivariate logistic regression was performed using sexual dysfunction, according to impairments shown by the FSFI, to evaluate factors associated with each domain. In all the models, the weights of the variables were adjusted for age. Odds ratios (ORs) and their 95% confidence intervals (95% CI) were obtained for each factor included in the model. All of the statistical tests were two-sided, and a p-value ≤ 0.05 was considered statistically significant. All statistical analyses were performed using SPSS version 16.0 (Chicago, IL, USA).

3. Results

3.1. Population Characteristics

Table 1 shows the general characteristics of the population, in addition to the sexual history of the patients with and without RA. We can observe that age was not different in the groups, with the median age for RA patients being 41 years (IQR 12), and for the control group, it was 42 (IQR 12) (p = 0.205). However, a difference is observed in the active workers (p < 0.001), the women with RA being less active. In addition, an association was found in the variables: use of contraceptives (p < 0.001), and intercourses per week >3 (p = 0.006); with respect to the group of women with RA, they have a minor frequency of these characteristics.

Table 1. General characteristics and sexual history of patients with rheumatoid arthritis and controls.

| Variable                                      | RA  n = 100 | Controls  n = 100 | p Value |
|-----------------------------------------------|-------------|------------------|---------|
| Age (years), median (IQR)                     | 41 (12)     | 42 (12)          | 0.205   |
| Married or cohabiting, n (%)                  | 82 (82)     | 82 (82)          | 1.00    |
| Active workers, n (%)                         | 19 (19)     | 35 (35)          | <0.001  |
| Menarche age (years), median (IQR)            | 12 (3)      | 12 (2)           | 0.59    |
| Oral contraceptive use, n (%)                | 3 (3)       | 63 (63)          | <0.001  |
| Oral contraceptives (months), median (IQR)    | 24 (61)     | 24 (54)          | 0.504   |
| Age at first intercourse (years), median (IQR)| 18 (3)      | 20 (6)           | <0.001  |
| Number of male sexual partners, median (IQR) | 1 (1)       | 1 (2)            | 0.302   |
| Intercourses per week > 3, n (%)              | 17 (17)     | 34 (34)          | 0.006   |
| Multiparity ≥3, n (%)                         | 79 (79)     | 79 (79)          | 1       |
| History of sexually transmitted infections, n (%)| 7 (7)       | 2 (2)            | 0.085   |
| DAS-28, median (IQR)                          | 4.89 (1.04) | -                | NC      |
| ESR, median (IQR)                             | 27 (12.8)   | -                | NC      |
| RF, median (IQR)                              | 18 (130)    | -                | NC      |

RA: Rheumatoid arthritis. DAS: Disease activity score. ESR: Erythrocyte sedimentation rate. RF: Rheumatoid factor. IQR: Interquartile range. Comparisons in median were made using the Mann–Whitney U test. Comparisons in proportions were made using the Chi-square test.

3.2. Sexual Dysfunction (FSFI Survey)

The scores for the different domains and the full-scale FSFI between the RA group and controls showed a higher prevalence of sexual dysfunction in the RA group compared with controls (p < 0.001), see Table 2.
Table 2. Comparison in FSFI score and frequency of sexual dysfunction between patients and controls.

| Domain                                      | RA n = 100 | Controls n = 100 | P  |
|---------------------------------------------|------------|-----------------|----|
| Presence of sexual dysfunction (global score <21.5), n (%) | 49 (49) | 25 (25) | <0.001 |
| Desire, median (IQR)                       | 2.4(1.2) | 3 (1.7) | <0.001 |
| Impairment in desire (<2.4), n (%)          | 30 (30) | 14 (14) | 0.006 |
| Arousal, median (IQR)                       | 2.8 (3.9) | 4.2 (1.8) | <0.001 |
| Impairment in arousal (<3.6), n (%)         | 50 (50) | 23 (23) | <0.001 |
| Lubrication, median (IQR)                   | 3.6 (5.4) | 5.1 (2.1) | <0.001 |
| Impairment in lubrication (<3.9), n (%)     | 52 (52) | 24 (24) | <0.001 |
| Orgasm, median (IQR)                        | 3.6 (4.7) | 4.8 (2.4) | <0.001 |
| Impairment in orgasm (<3.6), n (%)          | 49 (49) | 23 (23) | <0.001 |
| Satisfaction, median (IQR)                  | 4 (2.2) | 4.8 (2.4) | 0.014 |
| Impairment in satisfaction (<3.6), n (%)     | 32 (32) | 21 (21) | 0.08  |
| Pain intercourse, median (IQR)               | 4.4 (5.6) | 4.8 (2.4) | 0.003 |
| Impairment in pain intercourse (<3.6), n (%) | 36 (36) | 20 (20) | 0.01  |
| Global score, median (IQR)                  | 21.5 (20.5) | 27.2 (9.2) | <0.001 |

FSFI: Female Sexual Function Index. RA: Rheumatoid arthritis. IQR: Interquartile range. Low FSFI scores indicate impairment in sexual function. Range: For the global index, the scores range from 1.2 to 36 points. Impairment in each domain was computed as a score lower than 25th percentile for normal controls in our population. Comparisons in medians were made using the Mann–Whitney U test. Comparisons in proportions were made using the Chi-square test.

The comparison of the characteristics of patients with RA, with presence of sexual dysfunction versus those patients without sexual dysfunction, is shown in Table 3. Characteristics associated with sexual dysfunction in the RA group were: multiparity (p = 0.03), menopause (p = 0.001), higher HAQ-DI scores (p = 0.03); whereas methotrexate use was associated with a lower frequency of sexual dysfunction (p = 0.04).

Table 3. Characteristics associated with sexual dysfunction in patients with rheumatoid arthritis.

| Characteristics                  | Sexual Dysfunction n = 49 | Without Sexual Dysfunction n = 51 | P   |
|----------------------------------|---------------------------|-----------------------------------|-----|
| Age (years), median (IQR)        | 45 (6)                    | 40 (14)                           | 0.003|
| Married or cohabiting, n (%)     | 37 (76)                   | 45 (88)                           | 0.098|
| Intercourses per week, median (IQR) | 1 (2)                    | 2 (2)                             | 0.002|
| Multiparity ≥3, n (%)            | 43 (88)                   | 36 (71)                           | 0.03 |
| Oral contraceptives use, n (%)   | 2 (4)                     | 1 (2)                             | 0.52 |
| Menopause, n (%)                 | 14 (31)                   | 2 (4)                             | 0.001|
| Comorbidty, n (%)                | 30 (61)                   | 34 (67)                           | 0.57 |
| Disease duration (years), median (IQR) | 5 (9)                    | 6 (6.7)                           | 0.915|
| Morning stiffness, median (IQR)  | 50 (51)                   | 42 (48)                           | 0.323|
| Severity of pain, median (IQR)   | 52 (51)                   | 45 (61)                           | 0.309|
| HAQ-DI median (IQR)              | 0.77 (0.67)               | 0.44 (0.71)                       | 0.041|
| DAS 28, median (IQR)             | 4.8 (1.09)                | 4.9 (1.41)                        | 0.879|
| Sjögren syndrome, n (%)          | 17 (36)                   | 11 (22)                           | 0.12 |
| Rheumatoid nodules, n (%)        | 13 (28)                   | 7 (15)                            | 0.10 |
| Positive rheumatoid factor, n (%) | 29 (63)                   | 31 (64)                           | 0.87 |
| Prednisone use, n (%)            | 31 (70)                   | 33 (73)                           | 0.76 |
| Methotrexate use, n (%)          | 25 (52)                   | 33 (73)                           | 0.04 |

Morning stiffness, severity of pain and disease activity were evaluated with visual analogue scale from 0–100 mm. HAQ-DI score ranges 0 to 3. HAQ-DI: Health Assessment Questionnaire Disability Index. DAS28: Disease activity score. IQR interquartile range. Comparisons between median were made using Mann Whitney U-test. Comparisons between proportions were made with the Chi-square test.

Other variables related with lower scores in each domain of the FSFI from patients with RA were analyzed. We found an association of desire impairment with menopause (p < 0.01), higher HAQ-DI (p < 0.041), and those not treated with methotrexate (p = 0.05). The associated variables for arousal impairment were: lower intercourses per week (p < 0.01), menopause (p < 0.01), higher HAQ-DI (p = 0.02), the presence of Sjögren syndrome (p = 0.02),
and not using methotrexate ($p < 0.01$). The association to impairment in lubrication was related with fewer intercourses per week ($p = 0.01$), menopause ($p < 0.01$), higher HAQ-DI ($p = 0.02$), Sjögren syndrome ($p = 0.01$), and not using methotrexate in treatment ($p = 0.01$).

Table 4 shows the characteristics that correlated with the global score of sexual dysfunction and the scores in each domain for RA patients evaluated. In the global score, the variables that correlated with each domain were: age with arousal ($r = 0.329$, $p = 0.001$); lubrication ($r = -0.412$, $p \leq 0.001$); satisfaction ($r = -0.246$, $p = 0.014$) and global score ($r = -0.365$, $p < 0.001$); HAQ-DI with desire ($r = -0.242$, $p = 0.0016$); arousal ($r = -0.216$, $p = 0.032$); lubrication ($r = 0.250$, $p = 0.013$); satisfaction ($r = 0.246$, $p = 0.014$) and global score ($r = 0.261$, $p = 0.009$); functional class correlated with satisfaction ($r = -0.210$, $p = 0.040$).

| Characteristic                      | Desire | Arousal | Lubrication | Satisfaction | Orgasm | Pain | Global Score |
|-------------------------------------|--------|---------|-------------|--------------|--------|------|--------------|
| Age                                 | $-0.170$ | 0.092 | $-0.329$ | 0.001 | $-0.412$ | $<0.001$ | $-0.283$ | 0.004 | $-0.368$ | $<0.001$ | $-0.261$ | 0.009 | $-0.365$ | $<0.001$ |
| HAQ-DI                              | $-0.242$ | 0.016 | $-0.216$ | 0.036 | $-0.250$ | 0.013 | $-0.246$ | 0.014 | $-0.190$ | 0.061 | $-0.158$ | 0.121 | $-0.261$ | 0.009 |
| Functional Class                    | $-0.179$ | 0.081 | $-0.123$ | 0.234 | $-0.167$ | 0.104 | $-0.210$ | 0.040 | $-0.122$ | 0.237 | $-0.168$ | 0.101 | $-0.170$ | 0.097 |
| DAS28                               | $-0.072$ | 0.479 | $-0.100$ | 0.322 | $-0.112$ | 0.266 | $-0.133$ | 0.186 | $-0.113$ | 0.263 | $-0.078$ | 0.443 | $-0.123$ | 0.221 |
| Morning stiffness (last week)       | $-0.097$ | 0.344 | $-0.066$ | 0.518 | $-0.101$ | 0.324 | $-0.089$ | 0.381 | $-0.026$ | 0.801 | $-0.106$ | 0.299 | $-0.093$ | 0.362 |
| Disease activity (last week)        | $-0.085$ | 0.407 | $-0.100$ | 0.329 | $-0.143$ | 0.161 | $-0.151$ | 0.137 | $-0.089$ | 0.383 | $-0.159$ | 0.117 | $-0.129$ | 0.204 |
| Prednisone doses                     | 0.013   | 0.906 | $-0.108$ | 0.289 | $-0.092$ | 0.416 | $-0.113$ | 0.315 | $-0.060$ | 0.593 | $-0.123$ | 0.272 | $-0.068$ | 0.544 |
| Methotrexate doses                   | $-0.013$ | 0.906 | $-0.054$ | 0.632 | $-0.113$ | 0.319 | $-0.080$ | 0.481 | $-0.093$ | 0.410 | $-0.122$ | 0.281 | $-0.086$ | 0.447 |

HAQ-DI: Health Assessment Questionnaire Disability Index. DAS28: Disease activity score. Bivariate correlations, Spearman’s correlations.

3.3. Multivariate Analysis

The results of the multivariate analysis of characteristics associated with impairment in the FSFI and each component are shown in Table 5. In the logistic regression analysis, the factor associated with the presence of sexual dysfunction according to the global results of the FSFI was menopause (OR: 17.96, 95% CI: 2.10–35.37, $p = 0.008$), whereas, the use of methotrexate was observed as a protective factor (OR: 0.28, 95% CI: 0.10–0.77, $p = 0.01$). For each domain, there were different factors associated with impairment. Impairment in desire was associated with menopause (OR: 8.57, 95% CI: 1.89–38.91, $p = 0.005$) and higher scores on the HAQ-DI (OR: 3.47, 95% CI: 1.10–10.95, $p = 0.03$), whereas methotrexate was a protective factor (OR: 0.27, 95% CI: 0.09–0.86, $p = 0.03$). Menopause was associated with an impairment in arousal (OR: 8.10, 95% CI: 1.57–41.92, $p = 0.01$), whereas methotrexate still acted as a protective element (OR: 0.22, 95% CI: 0.08–0.59, $p = 0.003$). Impairment in lubrication was associated with a diagnosis of secondary Sjögren syndrome (OR: 5.84, 95% CI: 1.39–24.61, $p = 0.02$), methotrexate was again a protective factor (OR: 0.23, 95% CI: 0.08–0.68, $p = 0.008$). The domain of satisfaction was associated with menopause (OR: 6.10, 95% CI: 1.57–24.56, $p = 0.01$) and the use of methotrexate was protective (OR: 0.16, 95% CI: 0.06–0.49, $p = 0.001$). Impairment in orgasm only was associated with the patient’s age (OR: 1.09, 95% CI: 1.02–1.17, $p = 0.008$). Finally, an impairment in pain was associated with menopause (OR: 7.05, 95% CI: 1.72–28.81, $p = 0.007$).
Table 5. Adjusted analysis of factors associated with the presence of sexual dysfunction in rheumatoid arthritis.

| Variable | Method Enter | Method Forward Stepwise |
|----------|--------------|-------------------------|
|          | OR  | 95% CI | p  | OR  | 95% CI | p  |
| **Global score** | | | | | | |
| Age (years) | 1.05 | 0.98–1.13 | 0.20 | Not in the model | | |
| Menopause | 10.02 | 1.05–95.40 | 0.04 | 17.96 | 2.10–35.37 | 0.008 |
| HAQ–DI | 2.07 | 0.73–5.91 | 0.17 | Not in the model | | |
| Sjögren syndrome | 1.65 | 0.46–5.95 | 0.43 | Not in the model | | |
| Methotrexate use | 0.32 | 0.11–0.92 | 0.03 | 0.28 | 0.10–0.77 | 0.01 |
| **Impairment in desire** | | | | | | |
| Age (years) | 1.04 | 1.00–1.13 | 0.31 | Not in the model | | |
| Menopause | 4.50 | 1.00–20.11 | 0.05 | 8.57 | 1.89–38.91 | 0.005 |
| HAQ–DI | 3.51 | 1.14–10.81 | 0.03 | 3.47 | 1.10–10.95 | 0.03 |
| Methotrexate use | 0.33 | 0.10–0.90 | 0.05 | 0.27 | 0.09–0.86 | 0.03 |
| **Impairment in arousal** | | | | | | |
| Age (years) | 1.02 | 1.00–1.10 | 0.64 | Not in the model | | |
| Menopause | 7.09 | 1.21–41.23 | 0.03 | 8.10 | 1.57–41.92 | 0.01 |
| HAQ–DI | 2.29 | 0.81–6.45 | 1.19 | Not in the model | | |
| Methotrexate use | 0.23 | 0.08–0.64 | 0.005 | 0.22 | 0.08–0.59 | 0.003 |
| **Impairment in lubrication** | | | | | | |
| Age (years) | 1.03 | 0.96–1.12 | 0.37 | Not in the model | | |
| Menopause | 6.50 | 0.67–62.68 | 0.11 | Not in the model | | |
| HAQ–DI | 2.43 | 0.78–7.56 | 0.13 | Not in the model | | |
| Sjögren syndrome | 5.61 | 1.25–25.11 | 0.02 | 5.84 | 1.39–24.61 | 0.02 |
| Methotrexate use | 0.24 | 0.08–0.73 | 0.01 | 0.23 | 0.08–0.68 | 0.008 |
| **Impairment in satisfaction** | | | | | | |
| Age (years) | 1.07 | 1.00–1.16 | 0.12 | Not in the model | | |
| Menopause | 3.65 | 0.80–16.63 | 0.09 | 6.10 | 1.57–24.56 | 0.01 |
| HAQ–DI | 1.62 | 0.56–4.72 | 0.37 | Not in the model | | |
| Methotrexate use | 0.19 | 0.06–0.57 | 0.003 | 0.16 | 0.06–0.49 | 0.001 |
| **Impairment in orgasm** | | | | | | |
| Age (years) | 1.07 | 1.00–1.14 | 0.06 | 1.09 | 1.02–1.17 | 0.008 |
| Menopause | 2.55 | 0.55–11.75 | 0.23 | Not in the model | | |
| HAQ–DI | 1.87 | 0.70–4.98 | 0.21 | Not in the model | | |
| Methotrexate use | 0.40 | 0.15–1.07 | 0.07 | Not in the model | | |
| **Impairment in pain** | | | | | | |
| Age (years) | 1.03 | 0.96–1.11 | 0.38 | Not in the model | | |
| Menopause | 4.24 | 1.03–17.47 | 0.04 | 7.05 | 1.72–28.81 | 0.007 |
| HAQ–DI | 1.51 | 0.58–3.96 | 0.40 | Not in the model | | |
| Sjögren syndrome | 2.40 | 0.75–7.64 | 0.14 | Not in the model | | |
| Methotrexate use | 0.59 | 0.22–1.61 | 0.30 | Not in the model | | |

HAQ-DI: Health Assessment Questionnaire Disability Index. OR: Odds ratio. CI: 95% Confidence intervals. Analysis was performed using logistic regression. The dependent variable was sexual dysfunction (yes/no), or impairment in each domain. Statistical significance, \( p \leq 0.05 \).

4. Discussion

In this study, we estimate the prevalence and identified the factors associated with sexual dysfunction (SD) in Mexican women with RA. Previous studies have reported SD as more common among patients with RA compared to controls [5]. We observed that SD was highly prevalent in our studied population and all the domains evaluated were significantly affected. The domains most affected were lubrication, arousal, orgasm, pain during intercourse, satisfaction, and desire. Shahar, et al., also found differences in their results, observing lubrication problems in 17.6%, poor arousal in 21.6%, orgasmic disorder in 7.8%, and reported sexual pain disorder in 19.6%. Additionally, 49% of women did not obtain satisfaction and 31.4% had low desire [24]. SD is dependent on multiple causes that interact to produce the impairment. In this context, this study analyses a wide range of factors (epidemiological, gynecological, and factors specific to the disease) that may
influence the index score to evaluate sexual dysfunction in RA. In our study, we used the FSFI as an instrument to identify the presence of sexual dysfunction because the FSFI has been shown to be reliable, have discriminate and divergent validity to distinguish between groups, has a sensitivity to change, and is easy to administer requiring only about 15 min to complete [18,24]. The prevalence of sexual dysfunction among women with RA was evaluated in different independent studies [5,15,24–28]. Particularly, one of them observed that women with RA had a lower global score compared with controls [15]. A systematic review and meta-analysis included studies that evidenced patients with RA have a significantly increased risk of SD, suggesting that both patients and clinicians should be aware of the potential role of RA in the development of SD [29].

Thus in this study, we confirmed a high prevalence (49%) of SD in our patients with RA, similar to the results reported by Orzua-de la Fuente, et al. (51.9%) [30]. Both studies are significantly different in comparison to the study reported by Sahar et al., who observed a frequency of sexual dysfunction in 29.4% of Malaysian patients with RA, although, unfortunately, they did not include a comparison group [23]. Instead, in a study with Egyptian women, SD (with the FSFI) was reported in 45.7% of their patients with RA [25], a value similar to that observed in our study of Mexican women with RA. Factors associated with decreases in the FSFI were observed, showing a relationship between SD and menopause and a higher HAQ-DI score, although there was no relationship with the DAS28 in similarity with Aras, et al. [26]. These findings are different from those reported by others, who observed a correlation between the pain score and disease activity with SD [25], whereas these factors were not associated with the global index score in our patients. The difference in the findings observed among our RA patients could be related to their age, frequency of sexual intercourse, chronicity of symptoms, or the absence of acute disease during the performance of FSFI. The limitation in the performance of sexual intercourse was also observed using the HAQ-DI, identifying that 62% of RA patients had some difficulties, and 17% were completely unable to perform sexual intercourse due to arthritis [4]. Similar to our results, other studies have found a correlation between impairment in the HAQ-DI and sexual disability [26]. Likewise, this association between poor functioning and sexual dysfunction was also reported by Yilmaz et al., who observed a moderate negative correlation between the total FSFI score and the HAQ-DI [15].

In our experience, the HAQ-DI had a negative correlation with sexual parameters including impairments in desire, arousal, lubrication, satisfaction, and global score, whereas functional sexual class was negatively correlated with impaired satisfaction. A difference between our study and two other studies [14,24] is that we found a negative correlation between the prednisone dosage and the FSFI score in two domains, satisfaction and pain, whereas both referenced studies did not evaluate this correlation. On the other hand, one of them observed a negative correlation between the FSFI and DAS28 score, whereas we did not observe this correlation [14]. A possible reason to explain these differences is that their patients had higher disease activity in comparison with our RA patients; therefore, the effect of disease activity on the decrease in sexual function could be influenced by other factors.

Few studies are available for evaluating the factors associated with impaired sexual dysfunction. El-Miedany observed an association between sexual dysfunction and cardiovascular disease, pain score, hip joint involvement, disease activity, tender joint count, and the presence of secondary Sjögren syndrome [25]. We also observed an association between Sjögren syndrome and sexual dysfunction. In a mailed interview using a short version of the Questionnaire for Screening of Sexual Dysfunctions, van Berlo, et al. found that 51% of women with RA and/or Sjögren syndrome had interference with sexual activity caused by pain in their joints [31]. Differences in the methodology and instruments used to evaluate sexual function make it difficult to compare their findings with those of other studies. Similar to our results, others have not found a significant positive association between sexual dysfunction and DMARDs therapy and/or oral steroid therapy [25]. The significance of our study is based on the findings in the analysis, adjusted for age-associated female sexual dysfunction, of factors that were not analyzed in previous studies [15,24–27]; menopause...
was associated with global dysfunction and female sexual dysfunction in the domains of desire, arousal, and pain. We observed that sexual dysfunction is highly prevalent in women with no rheumatic disorders. Data produced from a national survey in the United States showed that women experience a loss of sexual interest and almost one-fourth do not experience orgasm [32]. One factor that could be associated with impaired FSFI score is age, as this was described in non-rheumatic populations [33]. Sexual dysfunction may diminish the competence of a patient to achieve satisfactory sexual intercourse with their partner, decreasing the quality of the relationship, and in extreme cases leading to marital unhappiness [34–36]. In several studies, about 50–95% of RA patients experienced problems during sexual intercourse, [27,28,33,34]. Likewise, one author reported a high prevalence of depression in women with RA who have sexual dysfunction compared with controls [15].

**Study Limitation**

Sexual distress is required to diagnose a disorder of sexual dysfunction. No measure of sexual distress was included, so the impairments in sexual function that we found do not necessarily indicate a full-fledged disorder of sexual function.

**5. Conclusions**

Sexual dysfunction is highly prevalent in Mexican women with RA, and this affected all of the domains evaluated. The factors associated with sexual dysfunction include menopause and a higher score on the HAQ-DI. More effort is required to establish a systematic assessment of this entity and its impact on quality of life.

**Author Contributions:** Conceptualization, M.S.-P. and W.R.-C.; Data curation, A.D.R.-M.; Investigation, M.S.-P., W.R.-C., V.D.-R., X.T., A.R.-C. and I.P.D.-R.; Methodology, M.S.-P., W.R.-C., V.D.-R., X.T., M.H., A.D.R.-M., B.T.-H. and I.P.D.-R.; Validation, X.T. and M.H.; Writing—original draft, M.S.-P., W.R.-C. and V.D.-R.; Writing—review & editing, M.S.-P., W.R.-C., V.D.-R. and I.P.D.-R. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Instituto Mexicano del Seguro Social R-2014-1301-59.

**Informed Consent Statement:** Informed consent was obtained from all subjects involved in the study.

**Data Availability Statement:** Data that support the findings of the study are available upon reasonable request.

**Acknowledgments:** An extensive gratitude to Raymond Rosen, for his permission to use the FSFI, and Rosa Cardenas for the statistical advise.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Chopra, A.; Abdel-Nasser, A. Epidemiology of rheumatic musculoskeletal disorders in the developing world. *Best Pr. Res. Clin. Rheumatol*. 2008, 22, 583–604. [CrossRef] [PubMed]

2. Alamanos, Y.; Voulgari, P.V.; Drosos, A.A. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: A systematic review. *Semin. Arthritis Rheum*. 2006, 36, 182–188. [CrossRef]

3. Moreno-Montoya, J.; Alvarez-Nemegyei, J.; Sanin, L.H.; Pérez-Barbosa, L.; Trejo-Valdivia, B.; Santana, N.; Goycochea-Robles, M.V.; Cardiel, M.H.; Riega-Torres, J.; Maradiaga, M.; et al. Association of regional and cultural factors with the prevalence of rheumatoid arthritis in the Mexican population: A multilevel analysis. *J. Clin. Rheumatol*. 2015, 21, 57–62. [CrossRef] [PubMed]

4. Abdel-Nasser, A.M.; Ali, E.I. Determinants of sexual disability and dissatisfaction in female patients with rheumatoid arthritis. *Clin. Rheumatol*. 2006, 25, 822–830. [CrossRef] [PubMed]

5. Khnaba, D.; Rostom, S.; Lahlou, R.; Bahiri, R.; Aboqal, R.; Hajaj-Hassouni, N. Sexual dysfunction and its determinants in Moroccan women with rheumatoid arthritis. *Pan Afr. Med. J*. 2016, 24, 16. [CrossRef]

6. Tristano, A.G. The impact of rheumatic diseases on sexual function. *Rheumatol. Int.* 2009, 29, 853–860. [CrossRef]
7. Puchner, R.; Sautner, J.; Gruber, J.; Bragagna, E.; Trenkler, A.; Lang, G.; Eberl, G.; Alkin, A.; Pieringer, H. High Burden of Sexual Dysfunction in Female Patients with Rheumatoid Arthritis: Results of a Cross-sectional Study. *J. Rheumatol.* 2019, 46, 19–26. [CrossRef]

8. Salonia, A.; Munariz, R.M.; Naspro, R.; Nappi, R.E.; Briganti, A.; Chionna, R.; Federghini, F.; Miron, V.; Rigatti, P.; Goldstein, L.; et al. Women’s sexual dysfunction: A pathophysiological review. *BJU Int.* 2004, 93, 1156–1164. [CrossRef]

9. Nasr, M.M.; El-Shafey, A.M. Sexual performance in rheumatoid arthritis patients—An unnoticed problem. *Egypt. Rheumatol.* 2013, 35, 201–205. [CrossRef]

10. Østensen, M. New insights into sexual functioning and fertility in rheumatic diseases. *Best Pr. Res. Clin. Rheumatol.* 2004, 18, 219–232. [CrossRef]

11. Carranza-Lira, S.; Núñez, F.D.C. Sexual dysfunction prevalence in a group of pre- and postmenopausal Mexican women. *Prz. Menopauzalny* 2018, 17, 39–42. [CrossRef] [PubMed]

12. Ledón, L.L.; Contreras-Yáñez, I.; Guarácha-Basáñez, G.; Valverde-Hernández, S.S.; González-Marín, A.; Ballinas-Sánchez, Á.D.J.; Durand, M.; Pascual-Ramos, V. Views of Mexican outpatients with rheumatoid arthritis on sexual and reproductive health: A cross-sectional study. *PloS ONE* 2021, 16, e0245538.

13. Rosen, R.; Brown, C.; Heiman, J.; Leiblum, S.; Meston, C.; Shabsigh, R.; Ferguson, D.; D’Agostino, R., Jr. The Female Sexual Function Index (FSFI): A multidimensional self-report instrument for the assessment of female sexual function. *J. Sex Marital Ther.* 2000, 26, 191–208. [CrossRef] [PubMed]

14. Meston, C.M. Validation of the Female Sexual Function Index (FSFI) in women with female orgasmic disorder and in women with hypoactive sexual desire disorder. *J. Sex Marital Ther.* 2003, 29, 39–46. [CrossRef] [PubMed]

15. Yilmaz, H.; Polat, H.A.; Yilmaz, S.D.; Erkin, G.; Kucuksen, S.; Sali, A.; Ugurlu, H. Evaluation of sexual dysfunction in women with rheumatoid arthritis: A controlled study. *J. Sex Med.* 2012, 9, 2664–2670. [CrossRef] [PubMed]

16. Twistmann Bay, L.; Graugaard, C.; Nielsen, D.S.; Möller, S.; Ellingsen, T.; Giraldi, A. Sexual Health and Dysfunction in Patients with Rheumatoid Arthritis: A Cross-sectional Single-Center Study. *Sex Med.* 2020, 8, 615–630.

17. Arnett, F.C.; Edworthy, S.M.; Bloch, D.A.; McShane, D.J.; Fries, J.F.; Kaplan, S.R.; Liang, M.H.; Luthra, H.S.; et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum.* Off. J. Am. Coll. Rheumatol. 1988, 31, 315–324. [CrossRef]

18. Jones, L.R. The use of validated questionnaires to assess female sexual dysfunction. *World J. Urol.* 2002, 20, 89–92. [CrossRef]

19. Meston, C.M.; Derogatis, L.R. Validated instruments for assessing female sexual function. *J. Sex Marital Ther.* 2002, 28 (Suppl. S1), 155–164. [CrossRef]

20. Wiegel, M.; Meston, C.; Rosen, R. The female sexual function index (FSFI): Cross-validation and development of clinical cutoff scores. *J. Sex Marital Ther.* 2005, 31, 1–20. [CrossRef]

21. Cardiel, M.H.; Abello-Banfi, M.; Ruiz-Mercado, R.; Alarcón-Segovia, D. How to measure health status in rheumatoid arthritis in non-English speaking patients: Validation of a Spanish version of the Health Assessment Questionnaire Disability Index (Spanish HAQ-DI). *Clin. Exp. Rheumatol.* 1993, 11, 117–121. [PubMed]

22. Prevooy, M.; van’t Hof, M.A.; Kuper, H.H.; van Leeuwen, M.A.; van de Putte, L.B.; van Riel, P.L. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. *Arthritis Rheum.* 1995, 38, 44–48. [CrossRef] [PubMed]

23. Regan-Smith, M.G.; O’Connor, G.T.; Kwok, C.K.; Brown, L.A.; Olmstead, E.M.; Burnett, J.B. Lack of correlation between the Steinbrocker staging of hand radiographs and the functional health status of individuals with rheumatoid arthritis. *Arthritis Rheum.* 1999, 42, 128–133. [CrossRef] [PubMed]

24. Shahar, M.A.; Hussein, H.; Sidi, H.; Shah, S.A.; Mohamed Said, M.S. Sexual dysfunction and its determinants in Malaysian women with rheumatoid arthritis. *Int. J. Rheum. Dis.* 2012, 15, 468–477. [CrossRef]

25. El Miedany, Y.; El Gaafary, M.; El Aroussy, N.; Youssef, S.; Ahmed, I. Sexual dysfunction in rheumatoid arthritis patients: Arthritis and beyond. *Clin. Rheumatol.* 2012, 31, 601–606. [CrossRef]

26. Aras, H.; Aras, B.; Icagasioglu, A.; Yumusakhyulu, Y.; Kemahli, E.; Haliloglu, S.; Oguz, F.M. Sexual dysfunction in women with rheumatoid arthritis. *Med. Glos.* 2013, 10, 327–331.

27. Coskun, B.; Coskun, B.N.; Atis, G.; Ergenekon, E.; Dilek, K. Evaluation of sexual function in women with rheumatoid arthritis. *Urol.* 2014, 10, 1081–1087.

28. Alia, F.; Rim, B.S.; Miladi, S.; Ouenniche, K.; Kassab, S.; Chekili, S.; Zakraoui, L.; Abdelghani, K.B.; Lataar, A. Comparison of sexual function in Tunisian women with rheumatoid arthritis and healthy controls. *Clin. Rheumatol.* 2019, 38, 3361–3365. [CrossRef]

29. Zhao, S.; Li, E.; Wang, J.; Luo, L.; Luo, J.; Zhao, Z. Rheumatoid arthritis and risk of sexual dysfunction: A systematic review and metaanalysis. *J. Rheumatol.* 2018, 45, 1375–1382. [CrossRef]

30. Orzuá-de la Fuente, W.M.; Salazar-Hernández, G.J.; Vega-Morales, D.; Garza-Alpírez, A.; Esquivel-Valerio, J.A. High Prevalence of Sexual Dysfunction in Women with Rheumatic Diseases: A not Recognized Health Domain. *Sex Disabil.* 2018, 36, 407–416. [CrossRef]

31. Van Berlo, W.T.; van de Wiel, H.B.; Taal, E.; Rasker, J.J.; Weijmar Schultz, W.C.; van Rijswijk, M.H. Sexual functioning of people with rheumatoid arthritis: A multicenter study. *Clin. Rheumatol.* 2007, 26, 30–38. [CrossRef] [PubMed]

32. Laumann, E.O.; Paik, A.; Rosen, R.C. Sexual dysfunction in the United States: Prevalence and predictors. *JAMA* 1999, 281, 537–544. [CrossRef] [PubMed]
33. Verit, F.F.; Verit, A.; Yeni, E. The prevalence of sexual dysfunction and associated risk factors in women with chronic pelvic pain: A cross-sectional study. *Arch. Gynecol. Obstet.* 2006, 274, 297–302. [CrossRef] [PubMed]

34. Elst, P.; Sybesma, T.; van der Stadt, R.J.; Prins, A.P.; Muller, W.H.; den Butter, A. Sexual problems in rheumatoid arthritis and ankylosing spondylitis. *Arthritis Rheum.* 1984, 27, 217–220. [CrossRef]

35. Blake, D.J.; Maisiak, R.; Brown, S.; Koplan, A. Acceptance by arthritis patients of clinical inquiry into their sexual adjustment. *Psychosomatics* 1986, 27, 576–579. [CrossRef]

36. Panush, R.S.; Mihailescuh, G.D.; Gornisiewicz, M.T.; Sutaria, S.H.; Wallace, D.J. Sex and arthritis. *Bull. Rheum. Dis.* 2000, 49, 1–4.